These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29278818)

  • 1. Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
    Chu LF; Rico T; Cornell E; Obasi H; Encisco EM; Vertelney H; Gamble JG; Crawford CW; Sun J; Clemenson A; Erlendson MJ; Okada R; Carroll I; Clark JD
    Drug Alcohol Depend; 2018 Feb; 183():176-183. PubMed ID: 29278818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.
    Chu LF; Sun J; Clemenson A; Erlendson MJ; Rico T; Cornell E; Obasi H; Sayyid ZN; Encisco EM; Yu J; Gamble JG; Carroll I; Clark JD
    J Addict Med; 2017; 11(5):342-349. PubMed ID: 28514235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study.
    Erlendson MJ; D'Arcy N; Encisco EM; Yu JJ; Rincon-Cruz L; Peltz G; Clark JD; Chu LF
    Am J Drug Alcohol Abuse; 2017 Jan; 43(1):78-86. PubMed ID: 27712113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: A functional magnetic resonance imaging study.
    Chu LF; Lin JC; Clemenson A; Encisco E; Sun J; Hoang D; Alva H; Erlendson M; Clark JD; Younger JW
    Drug Alcohol Depend; 2015 Aug; 153():314-22. PubMed ID: 26059463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia.
    Mahikhan F; Hashemian M; Dehesh T; Jafari E; Jafari M; Rahimi HR
    Curr Clin Pharmacol; 2019; 14(3):232-241. PubMed ID: 30706788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.
    Bergeria CL; Huhn AS; Tompkins DA; Bigelow GE; Strain EC; Dunn KE
    Drug Alcohol Depend; 2019 Sep; 202():111-114. PubMed ID: 31336328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
    Lofwall MR; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects.
    Sanders M; Jones S; Löwenstein O; Jansen JP; Miles H; Simpson K
    Pain Med; 2015 Aug; 16(8):1540-50. PubMed ID: 26110375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal symptoms predict prescription opioid dependence in chronic pain patients.
    Coloma-Carmona A; Carballo JL; Rodríguez-Marín J; Pérez-Carbonell A
    Drug Alcohol Depend; 2019 Feb; 195():27-32. PubMed ID: 30562677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats.
    Pinelli A; Trivulzio S; Tomasoni L
    Eur J Pharmacol; 1997 Dec; 340(2-3):111-9. PubMed ID: 9537805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
    Rehni AK; Bhateja P; Singh TG; Singh N
    Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
    Zhang G; Wu X; Zhang YM; Liu H; Jiang Q; Pang G; Tao X; Dong L; Stackman RW
    Neuropharmacology; 2016 Feb; 101():246-54. PubMed ID: 26432939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.